Literature DB >> 3840626

Adjuvant CMF chemotherapy in operable breast cancer: ten years later.

G Bonadonna, A Rossi, P Valagussa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3840626     DOI： 10.1007/bf01655184

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  13 in total

1.  Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens.

Authors:  C Brambilla; A Rossi; P Valagussa; G Bonadonna
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

Review 2.  Adjuvant systemic therapy for resectable breast cancer.

Authors:  G Bonadonna; P Valagussa
Journal:  J Clin Oncol       Date:  1985-02       Impact factor: 44.544

3.  Weight gain in women with breast cancer receiving adjuvant chemotherapy.

Authors:  M K Knobf; J C Mullen; D Xistris; D A Moritz
Journal:  Oncol Nurs Forum       Date:  1983       Impact factor: 2.172

4.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

5.  Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.

Authors:  P M Wilcox; J H Fetting; K M Nettesheim; M D Abeloff
Journal:  Cancer Treat Rep       Date:  1982-08

6.  Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.

Authors:  A Howell; H Bush; W D George; J M Howat; D Crowther; R A Sellwood; R D Rubens; J L Hayward; R D Bulbrook; I S Fentiman
Journal:  Lancet       Date:  1984-08-11       Impact factor: 79.321

7.  Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.

Authors:  G Bonadonna; P Valagussa; A Rossi; G Tancini; C Brambilla; M Zambetti; U Veronesi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

8.  Multimodal treatment in operable breast cancer: five-year results of the CMF programme.

Authors:  A Rossi; G Bonadonna; P Valagussa; U Veronesi
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-02

9.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.

Authors:  B Fisher; M Bauer; D L Wickerham; C K Redmond; E R Fisher; A B Cruz; R Foster; B Gardner; H Lerner; R Margolese
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
View more
  2 in total

Review 1.  Treatment of breast cancer in the 1990s. What does the future hold?

Authors:  R B Jones; E J Shpall
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

2.  Progesterone binding cyst protein (PBCP) in primary breast cancer: a new prognostic factor?

Authors:  J A Søreide; O A Lea; S Kvinnsland
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.